Discovery of robust and highly specific microbiome signatures of non-alcoholic fatty liver disease
Emmanouil Nychas,
Andrea Marfil-Sánchez,
Xiuqiang Chen,
Mohammad Mirhakkak,
Huating Li,
Weiping Jia,
Aimin Xu,
Henrik Bjørn Nielsen,
Max Nieuwdorp,
Rohit Loomba,
Yueqiong Ni,
Gianni Panagiotou
Affiliations
Emmanouil Nychas
Department of Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute
Andrea Marfil-Sánchez
Department of Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute
Xiuqiang Chen
Department of Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute
Mohammad Mirhakkak
Department of Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute
Huating Li
Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai Diabetes Institute
Weiping Jia
Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai Diabetes Institute
Aimin Xu
The State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong
Henrik Bjørn Nielsen
Clinical Microbiomics
Max Nieuwdorp
Amsterdam UMC, Location AMC, Department of Vascular Medicine, University of Amsterdam
Rohit Loomba
Department of Medicine, MASLD Research Center, University of California
Yueqiong Ni
Department of Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute
Gianni Panagiotou
Department of Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute
Abstract Background The pathogenesis of non-alcoholic fatty liver disease (NAFLD) with a global prevalence of 30% is multifactorial and the involvement of gut bacteria has been recently proposed. However, finding robust bacterial signatures of NAFLD has been a great challenge, mainly due to its co-occurrence with other metabolic diseases. Results Here, we collected public metagenomic data and integrated the taxonomy profiles with in silico generated community metabolic outputs, and detailed clinical data, of 1206 Chinese subjects w/wo metabolic diseases, including NAFLD (obese and lean), obesity, T2D, hypertension, and atherosclerosis. We identified highly specific microbiome signatures through building accurate machine learning models (accuracy = 0.845–0.917) for NAFLD with high portability (generalizable) and low prediction rate (specific) when applied to other metabolic diseases, as well as through a community approach involving differential co-abundance ecological networks. Moreover, using these signatures coupled with further mediation analysis and metabolic dependency modeling, we propose synergistic defined microbial consortia associated with NAFLD phenotype in overweight and lean individuals, respectively. Conclusion Our study reveals robust and highly specific NAFLD signatures and offers a more realistic microbiome-therapeutics approach over individual species for this complex disease. Video Abstract